WebApr 2, 2024 · Cytokinetics ( NASDAQ: CYTK ), a biopharmaceutical company, has developed an experimental drug, aficamten, designed to treat hypertrophic … WebApr 12, 2024 · Cytokinetics had a negative return on equity of 1,401.63% and a negative net margin of 410.89%. The firm’s revenue for the quarter was down 96.5% compared to …
Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks - Yahoo …
WebJul 19, 2024 · Twitter YouTube Discussion Boards CAPS - Stock Picking Community Other Services. The Ascent ... Shares of Cytokinetics (CYTK 7.16%) are up 48.4% as of … WebApr 13, 2024 · The projected fair value for Cytokinetics is US$38.04 based on 2 Stage Free Cash Flow to Equity. Cytokinetics' US$34.05 share price indicates it is trading at similar levels as its fair value estimate the smiling man game online
Cytokinetics Receives Complete Response Letter From FDA for …
WebWebsite: www.cytokinetics.com Headquarters: South San Francisco, CA Size: 201 to 500 Employees Founded: 1997 Type: Company - Public (CYTK) Industry: Biotech & Pharmaceuticals Revenue: Unknown / Non-Applicable Competitors: Ionis Pharmaceuticals, MyoKardia, PTC Therapeutics Create Comparison WebFeb 27, 2024 · C ytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big... WebFeb 27, 2024 · On Feb. 28, the FDA is set to decide on Cytokinetics ’ omecamtiv mecarbil (OM), a novel, selective cardiac myosin activator being evaluated for heart failure with reduced ejection fraction. The regulatory agency accepted the New Drug Application for OM in February 2024 and initially set a target action date of Nov. 30, 2024. the smiling man horror game